Original Article

Outcomes of patients older than 75 years with non-metastatic prostate cancer

Yoshiyasu Amiya, Yasutaka Yamada, Masahiro Sugiuра, Makoto Sasaki, Takayuki Shima, Noriyuki Suzuki, Hiroomi Nakatsu, Shino Murakami, Jun Shimazaki, *

a Department of Urology, Asahi General Hospital, Asahi, Japan
b Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

Received 13 April 2016; received in revised form 13 August 2016; accepted 2 December 2016
Available online 3 January 2017

KEYWORDS
Prostate cancer; Elderly; Androgen deprivation; Non-metastatic prostate cancer; Radiation therapy

Abstract  Objective: Prostate cancer in elderly patients was formerly treated with androgen deprivation therapy. Since the latter of the 1990s new technologies were introduced into treatments, then strategies have varied. We aimed to observe the outcomes of elderly patients treated during transition period and compare each stage with others.

Methods: During 2008 and 2010, 255 patients with prostate cancer older than 75 years were sequentially treated. With exception of patients with bone and/or visceral metastasis, outcomes of 199 patients with localized and locally advanced stages were examined. Complete records were obtained by the end of 2015.

Results: In total, 122 (61%), 28 (14%), 37 (19%) and 12 (6%) of patients were in stages T1c-T2a, T2b-c, T3 and T4, respectively. Patients generally presented with abnormal screening or lower urinary tract symptom. Seventy-one percent of patients received androgen deprivation therapy as monotherapy and 22% of the radiation-treated patients added androgen deprivation therapy. Patients in stage T1c-T2a and T2b-c showed a favorable prognosis. Some cancer death appeared in patients with T3 and T4 during observation periods. Twenty-seven percent of patients died from prostate cancer-independent complications: pneumonia, heart disease, and brain vascular disease. Tendency is similar to that of Japanese elderly male population. No remarkable side effects from androgen deprivation therapy were noticed.

* Corresponding author.
E-mail address: shimajun@opal.famille.ne.jp (J. Shimazaki).
Peer review under responsibility of Second Military Medical University.

http://dx.doi.org/10.1016/j.ajur.2016.12.001
2214-3882/© 2017 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Recently the incidence of prostate cancer has increased in Japan, with 98,000 cases and 12,200 deaths in 2015 [1]. This increase in patients is attributed to the prolonged life span, widely distributed screening and the routine assay of total prostate-specific antigen (PSA) for patients with lower urinary tract symptom. Approximately half of all prostate cancer deaths occurred in elderly patients over 70 years of age. Consequently, the management of elderly prostate cancer patients is a newly important issue. Prostate cancer in elderly patients exhibits equal or greater malignant properties than in younger patients [2].

Elderly prostate cancer was formerly treated with androgen deprivation therapy (ADT) as a pivotal standard. Since the latter of the 1990s, remarkable progress in technology, such as laparoscopic surgery, external beam radiation therapy with increased dosage and hypofractionation, and anticancer drugs, were introduced into management for elderly patients, and use of ADT was changed. Thereafter, there have been many discussions on the treatment of elderly patients [3–7]. Crucial aspects on management include age, life expectancy, comorbidity and predictive effect of treatment. To evaluate various treatment strategies, the present study was aimed to examine the outcomes of elderly patients variously treated between 2008 and 2010 as a transition period from ADT only to the outcomes of elderly patients.

2. Materials and methods

The ethical committee of the Asahi General Hospital approved this research. Between January 2008 and December 2010, 255 cases of prostate cancer who were over 75 years old were sequentially treated at Asahi General Hospital after informed consent was obtained. With the exception of patients with bone and/or visceral metastases, the outcomes of 199 patients with localized and locally advanced stages were followed up. These patients were in good health with a score of 0 or 1 on the Charlson risk index [8] before start of treatment. A complete record of patient outcomes was obtained by the end of 2015. A prostate biopsy was performed with 8–12 cores via the perineal route and histological classification was performed using the Gleason patterns modified in the International Society of Urological Pathology [9]. Staging was classified by National Comprehensive Cancer Network Guidelines 2014 [10]. PSA was assayed with an Architect PSA kit (Abbot, Chiba, Japan). PSA was determined every 3 months, and then every 6 months after treatment. Pretreatment assessment was performed with an echogram and whole body scan, and if necessary, magnetic resonance imaging and computed tomography of pelvic and abdominal areas.

Radical retropubic prostatectomy was performed with a regional lymphadenectomy. External beam radiation therapy was performed with 2 Gy/day to the prostate gland for a total of 66 Gy. Before radiation therapy 3 months of ADT were prescribed, and after radiation therapy ADT was continued for 2–3 years. Brachytherapy with iodine seeds was administered with 145 Gy of a prescription dose as a monotherapy according to the manual. ADT was performed as a monotherapy with an luteinizing hormone-releasing hormone (LHRH) analog and concomitant use of 80 mg of bicalutamide daily until PSA relapse. In some cases, surgical castration was used instead of LHRH. Relapse was judged by a linear increase of PSA, and when relapse occurred, other hormone therapy and/or chemotherapy were performed.

Statistical analysis was performed with the SPSS statistical software (ver 22, IBM-SPSS Inc, Tokyo, Japan). Follow-up time was measured from the date of treatment initiation. Survival was measured using the Kaplan–Meier method. A p value <0.05 was considered statistically significant.

3. Results

ADT was well tolerated in elderly patients who were accepted during the treatment periods. Hot flashes were controlled temporarily with the prescription of a weak progesterational agent. To prevent the loss of bone mineral density, supplementation with calcium and vitamin D was advised. Caution was paid for patients to heart disease, hypertension and diabetes. During ADT treatment, there were no serious adverse effects. The patients were satisfied with the adequate treatment of their prostate cancer.

One hundred and seven patients with T1c-T2a and all the patients with T2b-c received ADT and their outcomes were favorable. Fifteen patients with T1c-T2a were initially treated without ADT: active surveillance, operation and brachytherapy. Some experienced PSA relapse but they received ADT as delayed ADT, and thereafter revealed favorable outcome (Table 1). Their outcomes were included in the respective stage.

Prognosis was calculated on base in the respective stages. The overall survival rates were 77%, 76%, 52% and 35% in stages T1c-T2a, T2b-c, T3 and T4 at 5 years,
respectively (Fig. 1A). The overall survival rates in advanced stage patients were worse primarily because of the occurrence of cancer-specific death. The cause-specific survival rates were 100%, 94%, 89% and 48% in stages T1c-T2a, T2b-c, T3 and T4 at 5 years, respectively (Fig. 1B). The effect of ADT was therefore limited to the localized stage, and death from prostate cancer in localized stage was rare.

We found that 27% of patients died from causes other than prostate cancer: 26%, 36%, 27% and 17% in stages T1c-T2a, T2b-c, T3 and T4, respectively (Fig. 1B). The causes of death were as follows: 14 (26%) from other malignancies, 16 (29%) from pneumonia, 7 (13%) from heart disease, 7 (13%) from brain vascular disease and 10 (19%) from others. With the exception of patients in stage T4, the periods between diagnosis and death were rather long time with healthy life styles.

Table 1: Patient characteristics.

|              | T1c-T2a | T2b-c | T3   | T4   | Total |
|--------------|---------|-------|------|------|-------|
| No. of patients | 122     | 28    | 37   | 12   | 199   |
| Age (year)   | 79 (75–88) | 80 (75–85) | 80 (75–90) | 80 (75–84) | 79 (75–90) |
| Complain (n) |         |       |      |      |       |
| Screening    | 56      | 10    | 11   | 1    | 78    |
| LUTS         | 47      | 13    | 21   | 10   | 91    |
| Other urinary symptom | 19 | 5     | 5    | 1    | 30    |
| PSA (ng/mL)  | 9.2 (1–20) | 13.8 (3–44) | 30.9 (5–186) | 153.9 (112–1630) |
| Gleason score (n) |     |       |      |      |       |
| <6           | 30      | 4     | —    | —    | 34    |
| 3 + 4        | 32      | 4     | —    | —    | 36    |
| 4 + 3        | 15      | 3     | 5    | 1    | 24    |
| ≥8           | 45      | 17    | 32   | 11   | 105   |
| Treatment (n) |         |       |      |      |       |
| Active surveillance | 6  | —     | —    | —    | 6     |
| Operation    | 4       | —     | —    | —    | 4     |
| Brachytherapy | 5   | —     | —    | —    | 5     |
| External beam radiation | 33 | 4     | 4    | 2    | 43    |
| ADT          | 74      | 24    | 33   | 10   | 141   |
| Death        |         |       |      |      |       |
| Cancer-specific (n) | 1  | 1     | 4    | 4    | 10    |
| Duration (month) | 54 | 61    | 19 (12–22) | 39 (17–66) | 35 (12–61) |
| Others (n)   | 32      | 10    | 10   | 2    | 54    |
| Duration (month) | 39 (6–82) | 52 (24–74) | 38 (10–74) | 6 (5–7) | 40 (5–82) |

PSA, prostate specific antigen; ADT, androgen deprivation therapy; LUTS, lower urinary tract symptoms.

a Mean (range).

b Duration between treatment initiation and death.

4. Discussion

More than half of early stage prostate cancer is indolent cancer, which may not disturb daily life. Moreover, prostate cancer detected at the early stages proceeds slowly. These findings demonstrate that elderly patients who suspect less than 10 years of the remaining life need not treat thereafter. Conversely, life expectancy in patients who are treated in the early stages is predicted to be better compared to men without cancer [11]. Patients older than 80 years still die from prostate cancer [12], thus aggressive treatments are recommended in elderly patients [13–15]. Radical prostatectomy is considered in these patients [16,17]. Radiation therapy is also recommended [18]. In the present study, the average age of the patients was approximately 79 years. Therefore, they may be candidates for either aggressive or non-aggressive treatments.

According to Japanese Government Lifetable [19], average predictive time of life remaining for men who are 80 years is 8.8 years. The cause of death in elderly men is pneumonia, followed by malignant neoplasm, heart disease and brain vascular disease, and the causes of death in the present patients were the same as those found in the Japanese male population. Patients who died from causes independent of prostate cancer appeared to have the same life span as the general population of elderly men. This indicates that ADT may not cause the serious side effects including cardiovascular system.

During the treatment of prostate cancer patients, complications from other diseases are a serious issue. The estimation for the influence of comorbidities is performed using a Charlson score and its weighted method [20–22]. Patients with comorbidities tend to receive non-aggressive treatment [16,23,24]. Conservative treatment for elderly patients showed favorable results with a Gleason score of 5–7 but patients with a score of 8–10 had a serious prognosis [25]. Localized stage patients with a Charlson score of 0 and most patients with a Gleason score ≤7 had a good outcome. The similar tendency was obtained in the present study.

Although ADT is a milestone therapy for prostate cancer, adverse effects have been observed. Most serious events are cardiovascular disease and metabolic disturbances [26–28]. Care is required to mitigate adverse effect
Although the reason why Japanese patients with prostate cancer experience slight adverse effects by ADT is not explained, adverse events including cardiovascular disease certainly appear to be less in Japanese patients when compared to foreign reports. Chinese (from Taiwan province) men do not have a risk of coronary heart disease from ADT [31]. Treatment with ADT shows an anticancer effect and less of adverse events, thus it could be beneficial and not harmful [32,33]. To obtain more benefits from therapy, the use of ADT required to reduce more adverse events. In the present study, ADT was performed for a rather long time, but treatment duration may be considered. For this purpose, the treatment schedule will be improved to reduce adverse effects, such as intermittent administration [34].

Psychological deterioration was discussed in European studies [35]. The present patients approved prior to treatment and were satisfied with adequate anticancer treatment without anxiety from progression of disease and adverse effects. Although there did not seem to occur serious psychological trouble in Japan, it requires a psychological care.

Advanced prostate cancer is a fatal disease. Most of these cases progress to castration resistant disease 2–3 years after diagnosis [36]. Chemotherapy and next generation hormonal drugs are being developed, but their efficacy remains to be confirmed for elderly patients.

5. Conclusion

Patients with T1c-T2a and T2b-c prostate cancer may proceed to favorable course by treating with ADT as monotherapy or combined with radiotherapy. Although care is necessary, ADT was well tolerated and adverse effect was slight. ADT is one of the selective treatments for elderly localized prostate cancer. However, patients with locally advanced stage prostate cancer showed serious outcomes and management remains to be developed.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] National Institute of Cancer Research of Japan. http://gamnjoho.jp.
[2] Busch J, Magheli A, Leva N, Ferrari M, Kraer J, klopf C, et al. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int 2014;114:517–21.
[3] Roussael B, Ouellet GM, Mohile SG, Dale W. Prostate cancer in elderly men: screening, active surveillance, and definitive therapy. Clin Geriatr Med 2015;31:615–29.
[4] Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010;106:462–9.
[5] Berger I, Bohmier F, Ponholzer A, Madersbacher S. Prostate cancer in senior adults: over- or undertreated? Wien Med Wochenschr 2009;159:521–8.
[6] Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol 2014;20:2523–30.
[7] Tay KJ, Moul JW, Armstrong AJ. Management of prostate cancer in the elderly. Clin Geriatr Med 2016;32:113–32.
[8] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
[9] Epstein Ji, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1225–36.
[10] National Comprehensive Cancer Network Guidelines. Prostate Cancer ver 2.2016. NCCN.org. Port Washington PA USA. http://www.nccn.org/.
[11] Sammon JD, Abdollah F, D’Amico A, Gettman M, Haese A, Suardi N, et al. Predicting life expectancy in men diagnosed with prostate cancer. Eur Urol 2015;68:756–65.
[12] Fitzpatrick JM. Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU Int 2008;101:16–22.
[13] Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol 2015;68:53–68.
[14] Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015;68:680–6.
[15] Bakelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for old men with locally advanced prostate cancer. J Clin Oncol 2015;33:716–22.
16. Daskivich TJ, Lai J, Dick AV, Setodji CM, Hanley JM, Litwin MS, et al. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Cancer 2014;120:2432–9.

17. Mitsuzuka K, Arai Y. Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. Int J Clin Oncol 2014;19:793–879.

18. Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, et al. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer 2014;120:3642–50.

19. Life table. Ministry of Health, Labor and Welfare of Japan; 2015. www.mhlw.go.jp/toukei/saikin/hw/life/life14/index.html.

20. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013;158:709–17.

21. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Improved prediction of long-term, other cause mortality in men with prostate cancer. J Urol 2011;186:1868–73.

22. Daskivich TJ, Kwan L, Dash A, Greenfield S, Litwin MS. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer. Eur Urol 2014;66:1002–9.

23. Jespersen CG, Norgaard M, Jacobsen JB, Borre M. Patient comorbidity is associated with conservative treatment of localized prostate cancer. Scand J Urol 2015;22:1–5.

24. Kenzik KM, Morey MC, Cohen HJ, Sloane R, Demark-Wahnefried W. Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. J Geriatr Oncol 2015;6:424–32.

25. Lu-Yao GL, Albertsen PC, Moor DF, Lin Y, DiPaola RS, Yao SL. Fifteen year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. Eur Urol 2015;68:805–11.

26. D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–5.

27. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181:1996–2008.

28. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Hemelrijk MV. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer; A meta-analysis. Eur Urol 2015;68:386–96.

29. Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged >66 years. Eur J Surg Oncol 2015;41:1529–39.

30. Nguyen PL, Albilhal SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825–36.

31. Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 2015;4:128–32.

32. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan – analysis of primary androgen deprivation therapy on the basis of data collected by J-CP. Jpn J Clin Oncol 2007;37:775–81.

33. Kitagawa Y, Hinotsu S, Shigehara K, Nakashima K, Kawaguchi S, Yagashi H, et al. Japan cancer of the prostate risk assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol 2013;20:708–14.

34. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol 2015;17:1–10.

35. Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 2015;121:4286–99.

36. Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen doubling time and nadir prostate-specific antigen. Jpn J Clin Oncol 2008;38:36–42.